| 1 |
Weber W， Fussenegg er M. Artificial mammalian gene regulation networks-novel approaches for gene therapy and bioengineering. J Biotechnol， 2002，98（2-3）：161-187.
|
| 2 |
Hannon GJ， Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature， 2004，431（7006）：371-378.
|
| 3 |
Matsukura S， Jones PA， Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res， 2003，31（15）：e77.
|
| 4 |
Meissner A， Jaenisch R. Generation of nuclear transfer-derived pluripotent ES cells from cloned Cdx2-deficient blastocysts. Nature，2006，439（7073）：212-215.
|
| 5 |
Gossen M， Bujard H. Tight control of gene expression in mam malian cells by tetracycline responsive promoters. Proc Natl Acad Sci USA， 1992，89（12）：5547-5551.
|
| 6 |
Gossen M， Freundlieb S， Bender G， et al. Transcriptional acti vation by tetracyclines in mammalian cells. Science， 1995，268（5218）：1766-1769.
|
| 7 |
Li MJ， Rossi JJ. Lentiviral vector delivery of recombinant small interfering RNA expression cassettes. Methods Enzymol， 2005，392：218-226.
|
| 8 |
Ohkawa J， Taira K. Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter. Hum Gene Ther， 2000，11（4）： 577-585.
|
| 9 |
Gupta S， Schoer RA， Egan JE， et al. Inducible， reversible， and stable RNA interference in mammalian cells. Proc Natl Acad Sci USA，2004，101（7）：1927-1932.
|
| 10 |
Wiznerowicz M， Trono D. Conditional suppression of cellular genes： lentivirus vector-mediated drug-inducible RNA interference. J Virol，2003，77（16）：8957-8961.
|
| 11 |
Lagresle-Peyrou C， Yates F， Malassis-Seris M， et al. Long term immune reconstitution in RAG-1 deficient mice treated by retroviral gene therapy： a balance between efficiency and toxicity. Blood， 2005，107（1）：63-72.
|
| 12 |
Li L， Lin L， Michael Staver， et al. Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res， 2005，65（16）：7249-7258.
|
| 13 |
Ginhoux F， Turbant S， Gross DA， et al. HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system. Mol Ther， 2004，10（2）：279-289.
|
| 14 |
Lena AM， Giannetti P， Sporeno E， et al. Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helperdependent adenoviral vector. J Gene Med， 2005，7（8）：1086-1096.
|
| 15 |
Pankiewicz R， Karlen Y， Imhof MO， et al. Reversal of the silencing of tetracycline-controlled genes requires the coordinate action of distinctly acting transcription factors. J Gene Med， 2005，7（1）：117-132.
|
| 16 |
Wilfried Weber， Martin Fussenegger. Pharmacologic transgene control systems for gene therapy. J Gene Med， 2006，8（5）：535-556.
|
| 17 |
Hartenbach S， Fussenegger M. Autoregulated， bidirectional and multicistronic gas-inducible mammalian as well as lentiviral expression vectors. J Biotechnol， 2005，120（1）：83-98.
|
| 18 |
Kramer BP， Weber W， Fussenegger M. Artificial regulatory networks and cascades for discrete multilevel transgene control in mammalian cells. Biotechnol Bioeng， 2003，83（7）：810-820.
|
| 19 |
Kramer BP， Viretta AU， Daoud-El-Baba M， et al. An engineered epigenetic transgene switch in mammalian cells. Nat Biotechnol，2004，22（7）：867-870.
|
| 20 |
Kramer BP， Fussenegger M. Hysteresis in a synthetic mammalian gene network. Proc Natl Acad Sci USA， 2005， 102（27）：9517-9522.
|